Product Details
| Product Name:
Mupadolimab |
CAS No.:
2451856-97-4 |
| Purity:
> 95% |
Supply Ability:
10g |
| Release date:
2026/07/27 |
Product Introduction
Bioactivity
| Name | Mupadolimab |
| Description | Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells. |
| In vitro | Mupadolimab induces increased expression of markers associated with B cell maturation and antigen presentation, transformation into plasma cells, as well as increased secretion of IgM and IgG[1]. |
| In vivo | Mupadolimab (10 mg/kg; intraperitoneal injection; once daily for 15 days) stimulates antigen-specific humoral immunity in NSG-SGM3 mice infected with SARS-CoV-2[1]. |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Mupadolimab | CPI006 | CPI 006 | CD73 |
| Inhibitors Related | Ucenprubart | Oleclumab | AMPCP | AB-680 | CD73-IN-1 | Uliledlimab | MethADP | CD73-IN-4 | Dresbuxelimab | PSB-12379 ditriethylamine salt | CD73-IN-12 | CD73-IN-3 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States